Business Wire

IDEMIA

4.6.2021 16:16:11 CEST | Business Wire | Press release

Share
IDEMIA Collaborates With ClimateSeed to Invest in a Carbon Project in India to Offer Truly Sustainable Payment Cards

For decades, the “take-make-waste” model has ruled the global economy. However, we are now seeing a paradigm shift in Banks’ and fin techs’ strategic values; they are seeking a “reduce-recycle-offset” model to reduce their carbon footprint and preserve the planet. There is also an strong appetite in the market for greener solutions, as customers are becoming more deeply committed to the protection of the environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210604005402/en/

With GREENPAY, IDEMIA is taking an end-to-end sustainability approach to the entire payment card lifecycle - from chip module to card body, to digital customer onboarding, to card personalization & fulfillment, to transport, to recycling once expired. GREENPAY aims to minimize the carbon footprint of payment cards by reducing and recycling at every step of this life cycle. These efforts are dramatically decreasing the footprint and for the residual footprint, IDEMIA has collaborated with ClimateSeed, a leading social initiatives launched by BNP Paribas in collaboration with Nobel Peace Prize Laureate Prof. Yunus’ team.

ClimateSeed will help IDEMIA in offsetting and compensating the residual footprint with investment in various sustainability projects. These projects are not only doing the environment good, but also contributing to several of the other 16 United Nations’ sustainable development goals.

IDEMIA is proud to share that the first project in which we have chosen to invest thanks to our ClimateSeed partnership, is the India-based “Khasi Hills community Carbon project”, employing 5,000-plus people, conserving existing and regenerating degraded forests in Meghalaya, north-eastern India. The young, regenerating forests are absorbing carbon at an annual rate of 1.75 tC/ha.

Amanda Gourbault , IDEMIA Executive VP Financial Institutions, said: “We are proud to be living up to our climate change pledges. We believe we should take real-life steps to help preserve the environment. Thanks to our ClimateSeed partnership, we are doing our bit to achieving a zero carbon economy and to champion sustainable development.”

Arnaud Despontin , IDEMIA VP Corporate Social Responsibility, said: “This project is a major step towards the achievement of our CSR goals to uphold and step up our support for local communities - specifically the underprivileged - while advocating more effective environmental conservation. IDEMIA staff selected the following four key priorities in a company-wide survey: Climate action, no poverty, clean water,sanitation and quality education. This venture furthers three out of the four goals, namely climate action, quality education and reducing poverty.”

Amit Kakatikar , Regional Director- Financial Institutions, India, said: ‘From reducing the carbon footprint of the card to implementing eco-designed packaging, and replacing paper with digital services, everyone in the payment ecosystem has a part to play to ensure that we deliver to our consumers a payment tool with the lowest possible carbon footprint. There is only one planet Earth, we all have a responsibility to protect it. Our Banking and Fintech partners in India are excited to adopt Green payment initiatives. Their enthusiasm is further augmented by IDEMIA’s investment in a project that builds a better India.”

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.

Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.

For further details, go to www.idemia.com / and follow us @IDEMIAGroup on Twitter

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye